Funding for this research was provided by:
Novo Nordisk A/S
Text and Data Mining valid from 2018-10-06
Received: 11 May 2018
Accepted: 3 September 2018
First Online: 6 October 2018
Duality of interest
: Since completion of the Steno-2 21.2 year follow-up data acquisition, data management and interpretation, JO has been employed by Novo Nordisk Scandinavia, Denmark. EN is employed by Novo Nordisk A/S, Søborg, Denmark. HHP has equity interest in Merck, and receives consulting honoraria from AbbVie and Novartis. OP has equity interest in Novo Nordisk. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.